About the Event
When the Human Genome Project was completed some predicted we were just years away from eradicating cancer. Nearly 20 years later, it’s clear that’s not the case. Genetics-based oncology drug development is slow, expensive, and ineffective. On average it takes 15 years, costs $2.7B, and only 3 drugs in 100 make it through clinical trials.
Preverna has found a better way. By looking at individual proteins, they are able to understand the causes of the initiation and progression of a tumor in a way that genomics can’t. Their drug development process uses these insights and an AI-enabled platform to effectively target the most important events in the growth of a tumor and identify the exact right drugs to stop tumor growth.
Please join our webinar to hear Preverna Co-founder and CEO, Dr. Ashkan Afshin discuss the company’s revolutionary approach to cancer drug development and their three robust pipelines.